Jaglix

Sitagliptin, the active ingredient in Jaglix, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. The medication works by increasing incretin levels, which enhances insulin secretion and suppresses glucagon release, thereby helping to lower both fasting and post-prandial blood glucose concentrations.

GNH USA supplies Jaglix as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and adherence to regulatory standards across multiple regions.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone with diet and exercise. - Type 2 diabetes mellitus (combination therapy): added to metformin, sulfonylureas, or insulin to improve overall glycemic control. - Adjunct to lifestyle therapy: supports diet and exercise in achieving target HbA1c.

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient head pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Gastrointestinal discomfort: includes nausea, dyspepsia, or abdominal pain. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain that may indicate inflammation of the pancreas. - Severe allergic reactions: including angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Joint pain: unexplained arthralgia that can be disabling. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: abnormal liver function tests or hepatitis.

When prescribing sitagliptin, clinicians should consider several safety precautions to minimize risk. - Renal function: assess renal impairment before initiation and adjust dose if necessary. - Hypersensitivity: discontinue if rash, angioedema, or other allergic signs develop. - Pancreatitis: monitor for persistent abdominal pain and discontinue if pancreatitis is suspected. - Cardiovascular disease: use with caution in patients with heart failure. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its plasma levels or the efficacy of co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase sitagliptin exposure and risk of hypoglycemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin concentrations. - Insulin secretagogues (e.g., sulfonylureas): combined use may heighten hypoglycemia risk.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose control; monitor blood glucose. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Rifampin: may reduce sitagliptin effectiveness by inducing metabolism.